Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 352-354

  Ou, Sai Hong Ignatius ^a   Chalmers, Zachary R ^b   Azada, Michele C ^a   Ross, Jeffrey S ^b,c   Stephens, Philip J ^b   Ali, Siraj M ^b   Miller, Vincent A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOUNDATION MEDICINE   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

Comprehensive genomic profiling; ROS1 rearranged NSCLC; TMEM106B ROS1

Indexed keywords

CARBOPLATIN; CYTOKERATIN 7; PEMETREXED; THYROID TRANSCRIPTION FACTOR 1; MEMBRANE PROTEIN; NERVE PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN; TMEM106B PROTEIN, HUMAN;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CHROMOSOME 7P; COMPREHENSIVE GENOMIC PROFILING; DIMERIZATION; FEMALE; FUSION GENE; GENE FUSION; GENE IDENTIFICATION; GENOME ANALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; MALIGNANT PLEURA EFFUSION; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TMEM106B ROS1 FUSION GENE; ADENOCARCINOMA; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; NERVE TISSUE PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; TRANSLOCATION, GENETIC;

EID: 84929501704     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.03.014     Document Type: Article

References (11)

1. Shaw A.T., Ou S.H., Bang Y.J., Camidge D.R., Solomon B.J., Salgia R., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014, 371:1963-1971.
2. Ou S.H. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. J Clin Pathol 2013, 66:839-846.
3. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 31:543-550. 511.
4. Ou S.H., Azada M., Hsiang D.J., Herman J.M., Kain T.S., Siwak-Tapp C., et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014, 9:549-553.
5. Stagi M., Klein Z.A., Gould T.J., Bewersdorf J., Strittmatter S.M. Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol Cell Neurosci 2014, 61:226-240.
6. van Blitterswijk M., Mullen B., Nicholson A.M., Bieniek K.F., Heckman M.G., Baker M.C., et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (Berl) 2014, 127:397-406.
7. Gallagher M.D., Suh E., Grossman M., Elman L., McCluskey L., Van Swieten J.C., et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol (Berl) 2014, 127:407-418.
8. Ou S.H., Klempner S.J., Greenbowe J.R., Azada M., Schrock A.B., Ali S.M., et al. Identification of a novel HIP1-ALK fusion variant in non-small-cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to alectinib. J Thorac Oncol 2014, 9:1821-1825.
9. Yoshida A., Tsuta K., Wakai S., Arai Y., Asamura H., Shibata T., et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 2014, 27:711-720.
10. Suehara Y., Arcila M., Wang L., Hasanovic A., Ang D., Ito T., et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012, 18:6599-6608.
11. Drilon A., Wang L., Arcila M.E., Balasubramanian S., Greenbowe J.R., Ross J.S., et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in driver-negative lung adenocarcinomas. Clin Cancer Res 2015, January 7, [Epub ahead of print].